ClinicalTrials.gg
Active, not recruitingNCT04041050Updated Feb 14, 2025

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

A Phase 1 interventional study of Navitoclax and Ruxolitinib in Myeloproliferative Neoplasm, sponsored by AbbVie. Active, not recruiting at 42 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing ruxolitinib in Myeloproliferative Disorders — 2 open to participants now, 4 under way, none of them phase 3. ruxolitinib · Myeloproliferative Disorders.

Enrollment
5th of 19
85 · median 49
Started
2019
with 1 other
Phase 1
4 of 19
1 open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
AbbVie

Among the 19 studies testing ruxolitinib in Myeloproliferative Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 1, and was the 16th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

2 of the 19 studies testing ruxolitinib in Myeloproliferative Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing ruxolitinib in Myeloproliferative Disorders, or all of them as a file.
02

Study summary

There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable dose of ruxolitinib therapy for at least 12 weeks prior to study enrollment. In Part 3, all eligible participants will receive navitoclax, with the primary objective being to evaluate potential navitoclax effect on QTc prolongation. In Part 4, effect of navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib. In Part 5, all eligible participants will receive ruxolitinib twice daily and navitoclax once daily for drug-drug interaction (DDI) assessment, followed by continued administration of navitoclax in combination with ruxolitinib.

03

Conditions studied

  • Myeloproliferative Neoplasm

Keywords

  • Myeloproliferative Neoplasm (MPN)
  • Chronic myelomonocytic leukemia (CMML)
  • Polycythemia Vera (PV)
  • Essential Thrombocythemia (ET)
  • Myelofibrosis (MF)
  • cancer
  • navitoclax
  • ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parts 1 and 2:

  • Navitoclax Monotherapy (Part 1 Only - Japanese Participants):

    • Documented diagnosis of myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET) as defined by the World Health Organization (WHO) classification.
    • MF participants must have received and failed or are intolerant to ruxolitinib therapy.
    • ET or PV participants must be requiring cytoreduction who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
  • Navitoclax + ruxolitinib Combination Therapy (Part 2 Only - Japanese and Taiwanese Participants):

    • Has documented diagnosis of primary MF, post-polycythemia vera MF (PPV-MF), or post-essential thrombocythemia (PET-MF) as defined by the World Health Organization (WHO) classification.
    • Is ineligible or unwilling to undergo stem cell transplantation at time of study entry.
    • Has splenomegaly as defined by a spleen palpable >= 5 cm below costal margin or spleen volume >= 450 cm\^3 as assessed by magnetic resonance imaging (MRI) or computed topography (CT) scan.
    • Must have received ruxolitinib therapy for at least 12 weeks and be currently on a stable dose of ruxolitinib (as described in the protocol).
  • Must have adequate bone marrow, kidney, liver and hematology blood values as detailed in the study protocol.
  • Part 1 only: Cytoreduction for participants with ET and PV therapy within 14 days prior to the first dose of navitoclax will be allowed pending additional discussion with study doctor. Ruxolitinib for MF participants will not be allowed within 7 days prior to the first dose of study drug and during navitoclax administration.
  • (ECOG) performance status \<= 1.

Part 3, and Part 4 (Participants in US and Europe):

  • Part 3 Only: At screening or baseline (pre-dose on Day 1), participant has corrected for heart rate (QTc) interval by Fridericia's correction (QTcF) \<= 450 msec.
  • Participants with a documented diagnosis of primary or secondary MF, ET, PV or chronic myelomonocytic leukemia (CMML) as defined by the WHO classification.
  • Participants must be requiring treatment and have failed or are intolerant to at least one prior therapy or who refuse standard therapy.
  • ECOG performance status \<= 2.
  • Must have adequate bone marrow, kidney, liver and hematology blood values as detailed in the study protocol.

Part 5 (Participants in US and Europe):

  • Has a documented diagnosis of primary MF as defined by the WHO classification, post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF.
  • Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System (DIPSS).
  • Requiring treatment for MF and must either have no prior treatment with a JAK2 inhibitor or have received treatment with ruxolitinib as noted in the protocol.
  • Have an ECOG performance status \<=2.
  • Have adequate bone marrow, kidney, liver and hematology blood values as detailed in the protocol.

Exclusion criteria

Exclusion Criteria:

Part 1 and 2:

  • Shows leukemic transformation (> 10% blasts in peripheral blood or bone marrow ).
  • Has a history of an active other than MPN within the past 2 years prior to study entry (exceptions detailed in the protocol).
  • Has a positive test result for at screening.
  • Has chronic active virus (HBV) or virus (HCV) infection requiring treatment.
  • Has evidence of other uncontrolled condition(s).
  • Has previously taken a BH3 mimetic compound.
  • Currently on medications that interfere with coagulation (including warfarin) or function with the exception of low dose aspirin (up to 100 mg) and low-molecular-weight heparin (LMWH).
  • Has received strong or moderate inhibitors (e.g., ketoconazole, clarithromycin) within 14 days prior to the administration of the first dose of navitoclax.

Part 3, and Part 4:

  • Had prior therapy with a BH3 mimetic compound.
  • Have received strong or moderate CYP3A inhibitors within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of navitoclax.
  • Have received strong CYP3A inducers within 10 days prior to the first dose of navitoclax.
  • Show leukemic transformation (> 10% blasts in peripheral blood or bone marrow biopsy).
  • Currently on medications that interfere with coagulation (including warfarin) or platelet function except for low-dose aspirin (up to 100 mg) and LMWH.

Part 4 Only:

  • Have received CYP2C9 inhibitors within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of study drugs.
  • Have received CYP2C9 inducers within 10 days prior to the first dose of study drugs.

Part 5 Only:

  • Have accelerated MF, defined as > 10% blasts in peripheral blood or bone marrow aspirate and biopsy.
  • Eligible for stem cell transplantation at time of study entry.
  • Had prior therapy with a BH3 mimetic compound or BET inhibitor.
  • Currently on medications that interfere with coagulation (including warfarin) or platelet function except for low-dose aspirin (up to 100 mg) and LMWH.
  • Have received strong CYP3A inhibitors or CYP2C9 inhibitors within 28 days of 5 half-lives of the drug (whichever is shorter) prior to the first dose of study drugs.
  • Have received strong CYP3A inducers or CYP2C9 inducers within 10 days prior to the first dose of study drugs.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Part 1: Navitoclax Monotherapy

    Participants will receive various doses of navitoclax once daily (QD).

    Drug: Navitoclax

  • Experimental
    Part 2: Navitoclax + Ruxolitinib Combination Therapy

    Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).

    Drug: Navitoclax · Drug: Ruxolitinib

  • Experimental
    Part 3: Navitoclax Monotherapy

    Participants will receive navitoclax once daily (QD).

    Drug: Navitoclax

  • Experimental
    Part 4: Navitoclax + Celecoxib

    Participants will receive navitoclax once daily (QD) starting on Day 3. Participants will also receive celecoxib single dose on Day 1 and Day 7.

    Drug: Navitoclax · Drug: Celecoxib

  • Experimental
    Part 5: Navitoclax + Ruxolitinib Combination Therapy

    Participants will receive ruxolitinib BID and navitoclax QD for drug-drug interaction (DDI) assessment, followed by continued administration of navitoclax in combination with ruxolitinib.

    Drug: Navitoclax · Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLT) (Part 1 and Part 2)

    Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 28-day cycle of navitoclax.

    Time frame: Up to 28 days after the navitoclax initiation

  2. Maximum Observed Plasma Concentration (Cmax) of Navitoclax (Part 2 and 5)

    Maximum Observed Plasma Concentration (Cmax) of Navitoclax.

    Time frame: Up to approximately 1 day

  3. Maximum Observed Plasma Concentration (Cmax) of Celecoxib (Part 4)

    Maximum Observed Plasma Concentration (Cmax) of Celecoxib.

    Time frame: Up to approximately 1 day

  4. Time to Cmax (peak time, Tmax) of Navitoclax (Part 2 and 5)

    Tmax defined as time to maximum observed plasma concentration of Navitoclax.

    Time frame: Up to approximately 1 day

  5. Time to Cmax (peak time, Tmax) of Celecoxib (Part 4)

    Tmax defined as time to maximum observed plasma concentration of Celecoxib.

    Time frame: Up to approximately 1 day

  6. Area Under the Plasma Concentration-time Curve from time 0 to the time of the last measurable concentration (AUCt) of Navitoclax

    Area under the plasma concentration-time curve from time zero to the last measurable concentration of Navitoclax.

    Time frame: Up to approximately 2 days

  7. Area Under the Plasma Concentration-time Curve from time 0 to the time of the last measurable concentration (AUCt) of Celecoxib (Part 4)

    Area under the plasma concentration-time curve from time zero to the last measurable concentration of Celecoxib.

    Time frame: Up to approximately 2 days

  8. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years).

  9. Change in QT interval corrected for heart rate interval by Fridericia's correction formula (QTcF) (Part 3)

    Change in QTcF (Part 3).

    Time frame: From first dose of study drug until 30 days following last dose of study drug.

Secondary outcomes

  1. Overall Response Rate

    ORR according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment/European Leukemia Net (IWG-MRT/ELN) criteria for participants with myelofibrosis, essential thrombocythemia, and polycythemia vera, and according to IWG criteria for participants with CMML.

    Time frame: Up to approximately 96 weeks

07

Study locations

42 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Dec 2026, 85 months after the start.

Of 40 phase 1 interventional studies under Myeloproliferative Disorders, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 140. This study's planned 85 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 1, 2019
StartActual
Nov 8, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04041050
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Nov 8, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 14, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Navitoclax · Ruxolitinib

Start the discussion